SEC Form 4 · accession 0001185185-17-000411
U.S. Stem Cell, Inc. · USRM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mike Tomas
Officer — CEO & President · Director
Period of report
Feb 6, 2017
Accepted (ET)
Feb 17, 2017 · 4:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001388319
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 9,793 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.0043 | Feb 6, 2017 | A | 10,000,000 | A | — | Feb 6, 2027 | Common Stock | 10,000,000 | 21,841,284 | D |
Explanation of responses
- F12,500,000 vest on 02/06/2018, 2,500,000 vest on 02/06/2019, 2,500,000 vest on 02/06/2020, and 2,500,000 vest on 02/06/2021.